1
|
Poorthuis MH, Brand EC, Hazenberg CE, Schutgens RE, Westerink J, Moll FL, de Borst GJ. Plasma fibrinogen level as a potential predictor of hemorrhagic complications after catheter-directed thrombolysis for peripheral arterial occlusions. J Vasc Surg 2017; 65:1519-1527.e26. [DOI: 10.1016/j.jvs.2016.11.025] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2016] [Accepted: 11/10/2016] [Indexed: 10/20/2022]
|
2
|
Arko FR, Cipriano P, Lee E, Filis KA, Zarins CK, Fogarty TJ. Treatment of Axillosubclavian Vein Thrombosis: A Novel Technique for Rapid Removal of Clot Using Low-Dose Thrombolysis. J Endovasc Ther 2016; 10:733-8. [PMID: 14533970 DOI: 10.1177/152660280301000408] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Purpose: To report successful combined percutaneous mechanical thrombectomy and pharmacological lysis for axillosubclavian vein thrombosis, with rapid clot removal at a single setting using low-dose thrombolysis. Case Reports: Two consecutive patients presented with arm swelling; the diagnosis of axillosubclavian vein thrombosis was confirmed with duplex ultrasound. Both patients were treated percutaneously with the Solera mechanical thrombectomy device, after which 5 mg of tissue plasminogen activator were delivered within ∼10 minutes via the Trellis infusion catheter to remove any residual thrombus. Completion venography and serial duplex ultrasound scans in follow-up demonstrated widely patent axillosubclavian veins with no residual thrombus in both cases. Conclusions: Standard treatment of axillosubclavian vein thrombosis may require 12 to 36 hours, with multiple trips to the angiography suite. The novel technique combining mechanical thrombectomy and pharmacological lysis can be performed safely and successfully at a single setting with a small dose of the lytic drug.
Collapse
Affiliation(s)
- Frank R Arko
- Division of Vascular Surgery, Stanford University Medical Center, Stanford University, Stanford, California 94305, USA.
| | | | | | | | | | | |
Collapse
|
3
|
Falkowski A, Poncyljusz W, Samad R, Mokrzyński S. Safety and Efficacy of Ultra-high-dose, Short-term Thrombolysis with rt-PA for Acute Lower Limb Ischemia. Eur J Vasc Endovasc Surg 2013; 46:118-23. [DOI: 10.1016/j.ejvs.2013.04.016] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2012] [Accepted: 04/10/2013] [Indexed: 11/26/2022]
|
4
|
Karnabatidis D, Spiliopoulos S, Tsetis D, Siablis D. Quality improvement guidelines for percutaneous catheter-directed intra-arterial thrombolysis and mechanical thrombectomy for acute lower-limb ischemia. Cardiovasc Intervent Radiol 2011; 34:1123-36. [PMID: 21882081 DOI: 10.1007/s00270-011-0258-z] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2010] [Accepted: 07/27/2011] [Indexed: 02/08/2023]
Abstract
Percutaneous catheter-directed intra-arterial thrombolysis is a safe and effective method of treating acute and subacute lower limb ischemia, as long as accurate patient selection and procedural monitoring are ensured. Although larger, controlled trials are needed to establish the role of PTDs in ALI, mechanical thrombectomy could currently be applied combined with lytic infusion in selected cases where rapid recanalization is required or as a stand-alone therapy when the administration of thrombolytic agents is contraindicated.
Collapse
Affiliation(s)
- Dimitris Karnabatidis
- Department of Radiology, Patras University Hospital, School of Medicine, Rion, Greece.
| | | | | | | |
Collapse
|
5
|
Chasing Clot: Thrombophilic States and the Interventionalist. J Vasc Interv Radiol 2009; 20:1403-16; quiz 1417. [DOI: 10.1016/j.jvir.2009.08.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2009] [Revised: 07/07/2009] [Accepted: 08/24/2009] [Indexed: 01/08/2023] Open
|
6
|
Morris J, Neaton M. Continuous improvement process for a high-risk population: Catheter-directed thrombolytic infusions. JOURNAL OF VASCULAR NURSING 2009; 27:8-12. [DOI: 10.1016/j.jvn.2008.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2008] [Revised: 10/22/2008] [Accepted: 10/28/2008] [Indexed: 11/17/2022]
|
7
|
|
8
|
Successful intra-arterial alteplase infusion is a predictor of 12-month limb survival in patients with lower limb arterial occlusion. Clin Radiol 2008; 63:636-41. [DOI: 10.1016/j.crad.2007.10.017] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2007] [Revised: 10/17/2007] [Accepted: 10/26/2007] [Indexed: 11/20/2022]
|
9
|
Tepe G, Wiskirchen J, Pereira P, Claussen CD, Miller S, Duda SH. GP IIb/IIIa Blockade During Peripheral Artery Interventions. Cardiovasc Intervent Radiol 2007; 31:8-13. [PMID: 17479207 DOI: 10.1007/s00270-005-0266-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The activation of the platelet GP IIb/IIIa receptor is the final and common pathway in platelet aggregation. By blocking this receptor, platelet aggregation can be inhibited independently of the stimulus prompted the targeting of this receptor. Several years ago, three drugs have been approved for coronary artery indications. Since that time, there is increasing evidence that GP IIb/IIIa receptor blockade might have also an important role in peripheral arterial intervention. This article summarizes the action and differences of GP Ilb/IIIa receptor inhibitors and its possible indication in peripheral arteries.
Collapse
Affiliation(s)
- Gunnar Tepe
- Department of Diagnostic Radiology, University of Tübingen, 72076, Tübingen, Germany.
| | | | | | | | | | | |
Collapse
|
10
|
Sajid MS, Ahmed N, Desai M, Baker D, Hamilton G. Upper limb deep vein thrombosis: a literature review to streamline the protocol for management. Acta Haematol 2007; 118:10-8. [PMID: 17426392 DOI: 10.1159/000101700] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2006] [Accepted: 02/06/2007] [Indexed: 11/19/2022]
Abstract
OBJECTIVE The objective of this article is to provide up-to-date information about aetiology, pathogenesis, diagnostic modalities and treatment of upper limb deep vein thrombosis (ULDVT). METHODS Generic terms including ULDVT, axillary-subclavian DVT, and complications of central venous catheters were searched on electronic database. We analysed original studies, review articles and evaluation studies published over the last 25 years. RESULTS Forty-seven studies on ULDVT encompassing 2,557 patients were evaluated. The incidence of ULDVT was quoted 1-4% of the total DVT. Primary ULDVT (20% of the total) was due to activity-related venous trauma. Secondary ULDVT (80% of the total) was due to central venous catheters and malignancy. Duplex ultrasound (sensitivity 78-100% and specificity 82-100%), contrast venography (gold standard) and magnetic resonance venography were the diagnostic tools used. Pulmonary embolism (2-35%) and post-thrombotic syndrome (7-46%) were the main sequelae. Anticoagulation was the universal intervention, giving 79% symptom relief (13.2% rethrombosis rate). Thrombolysis and/or percutaneous thrombectomy were used in 38% of cases for the management of ULDVT, giving 83% symptom relief (90% recanalization rate and 9% rethrombosis rate). Surgical decompression, venous angioplasty and superior vena cava filters were the main adjunctive interventions. CONCLUSION ULDVT, although rare, is associated with considerable morbidity and mortality (29-40%) due to potential risks of pulmonary embolism, post-thrombotic syndrome and loss of vascular access. Simple anticoagulation is suitable for the majority of patients. Thrombolysis/thrombectomy is often successful but less frequently used. Surgical decompression, venous angioplasty and superior vena cava filters have some role in recurrent cases. An optimal management protocol can be established using a multimodality approach.
Collapse
Affiliation(s)
- Muhammad S Sajid
- Department of Vascular Surgery, Royal Free Hospital, Hampstead, London, UK.
| | | | | | | | | |
Collapse
|
11
|
Chan J, Rees CR, Song AK, Pham S. Usefulness of catheter-directed thrombolysis using alteplase in peripheral vascular occlusion. Proc AMIA Symp 2005; 14:3-7. [PMID: 16369579 PMCID: PMC1291304 DOI: 10.1080/08998280.2001.11927723] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
Abstract
This study evaluated the safety and efficacy of alteplase in catheter-directed treatment for peripheral arterial and venous thrombosis and considered the optimal dosing regimen. Forty-four patients (49 encounters) underwent transcatheter therapy using alteplase between January and November 1999. The most common indications for thrombolysis were peripheral arterial occlusion (PAO) and venous thrombosis (38 patients, 43 encounters). Each encounter was reviewed for indication, dosage of alteplase, duration of infusion, concomitant use of anticoagulation, degree of lysis, and complications. Patients were divided into low-dose (0.5 to 1.0 mg/hr), mid-dose (1.0 to 1.5 mg/hr), and high-dose (>1.5 mg/hr) groups. For PAO, there was no significant difference in the success rate between the 3 dose groups. A lower complication rate was achieved in the low-dose group. For venous thrombosis, there was no difference in the overall success or complication rates for each of the 3 groups. Partial lysis was achieved more readily in the mid and high-dose groups, but the risk of serious complications was greater. Overall, the complete thrombolysis rate was 71% for PAO and 55% for venous thrombosis. Major and minor complication rates were 7% and 19%, respectively. An equivalent success rate with a lower complication rate can be achieved using a low-dose constant catheter-directed infusion of alteplase for cases of PAO. Cases of venous thrombosis had a lower overall success rate compared with PAO. A mid-dose infusion of alteplase can achieve greater complete and partial thrombolysis rates without increasing the complication rate. Major and minor complication rates were similar to the rates given in the published literature.
Collapse
Affiliation(s)
- J Chan
- Department of Radiology, Vascular and Interventional Section, Baylor University Medical Center, Dallas, Texas 75246, USA
| | | | | | | |
Collapse
|
12
|
Schoots IG, Levi MM, Reekers JA, Lameris JS, van Gulik TM. Thrombolytic therapy for acute superior mesenteric artery occlusion. J Vasc Interv Radiol 2005; 16:317-29. [PMID: 15758127 DOI: 10.1097/01.rvi.0000141719.24321.0b] [Citation(s) in RCA: 119] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The aim of this review is to evaluate thrombolytic therapy for acute superior mesenteric artery occlusion as an alternative or adjunctive treatment modality to surgical therapy and to provide current knowledge for timely and informed decisions regarding treatment of acute mesenteric ischemia. A systematic analysis of the available literature from 1966 to 2003 regarding thrombolytic therapy for superior mesenteric artery thromboembolism was performed. A total of 20 case reports and seven small series covered 48 patients with acute superior mesenteric artery thromboembolism. In the herein reviewed series, thrombolytic therapy of acute superior mesenteric artery thromboembolism resulted in angiographic resolution of the thromboembolism in 43 patients, in clinical success without requiring additional surgical intervention in 30 patients, and in survival in 43 patients, with similar complication rates as in thrombolytic treatment of peripheral vascular occlusions. Remission of abdominal pain during the first few hours of treatment formed the most important indicator of therapeutic success. Insufficient evidence from reviewed literature is available to determine the relative effectiveness and safety of thrombolytic treatment for acute superior mesenteric artery thromboembolism; however, initial results appear to be promising. Thrombolytic therapy can be effective relatively quickly, may obviate surgery, and has the potential to resolve the clot completely. In some cases it can be used as an alternative or neo-adjunctive treatment modality to surgery. A treatment guideline for thrombolysis of acute superior mesenteric artery thromboembolism should be developed.
Collapse
Affiliation(s)
- Ivo G Schoots
- Department of Surgery, Academic Medical Center, University of Amsterdam, Department of Surgery, IWO-1-155, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands.
| | | | | | | | | |
Collapse
|
13
|
Temple M, Williams S, John P, Chait P, Connolly B. Percutaneous treatment of pediatric thrombosis. Eur J Radiol 2005; 53:14-21. [PMID: 15607849 DOI: 10.1016/j.ejrad.2004.07.020] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2004] [Revised: 07/20/2004] [Accepted: 07/26/2004] [Indexed: 10/26/2022]
Abstract
While rare, thrombosis in the pediatric population can result serious sequelae including death. The best treatment options have not yet been firmly established for this age group. During childhood, there are age-related changes in components of the coagulation system that can affect treatment choices. This review article gives an overview of pediatric coagulation and describes the current state of percutaneous treatment options including local thrombolysis and thrombectomy.
Collapse
Affiliation(s)
- Michael Temple
- Department of Diagnostic Imaging, Centre for Image Guided Therapy, Hospital for Sick Children, University of Toronto, Toronto, Canada.
| | | | | | | | | |
Collapse
|
14
|
Gates J, Hartnell GG. When Urokinase Was Gone: Commentary on Another Year of Thrombolysis Without Urokinase. J Vasc Interv Radiol 2004; 15:1-5. [PMID: 14709680 DOI: 10.1097/01.rvi.0000106384.63463.a5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Affiliation(s)
- Julia Gates
- Department of Radiology, Baystate Medical Center, 790 Chestnut Street, Springfield, MA 01199, USA
| | | |
Collapse
|
15
|
Connors JJ. Pharmacologic Agents in Stroke Prevention, Acute Stroke Therapy, and Interventional Procedures. J Vasc Interv Radiol 2004; 15:S87-101. [PMID: 15101518 DOI: 10.1097/01.rvi.0000112975.88422.5d] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Pharmaceutical agents have moved far beyond just the aspirin and heparin that were the mainstays of stroke and interventional therapy as recently as 10 to 15 years ago. Our understanding of the mechanisms of thrombus formation and vascular response to damage as well as our armamentarium has tremendously improved in the past decade. Direct thrombin inhibitors, powerful antiplatelet agents, new fibrinolytic agents, and statins now allow far greater manipulation of the intraprocedural and postprocedural clot cascade and atherogenesis. It is mandatory that current-day interventionists understand the correct and appropriate use of these agents to achieve the desired outcomes of therapy.
Collapse
Affiliation(s)
- J J Connors
- Department of Interventional Neuroradiology, Miami Cardiovascular Institute, Baptist Hospital, 8900 North Kendall Drive, Miami, Florida 33176, USA.
| |
Collapse
|
16
|
Ouriel K. Endovascular techniques in the treatment of acute limb ischemia: thrombolytic agents, trials, and percutaneous mechanical thrombectomy techniques. Semin Vasc Surg 2003; 16:270-9. [PMID: 14691769 DOI: 10.1053/j.semvascsurg.2003.08.004] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Acute peripheral arterial occlusion is associated with great risk to the patient's limb and life. Failure to restore adequate arterial flow in a timely fashion can result in the development of irreversible tissue infarction and the opportunity for limb salvage is lost. On the other hand, patients with acute limb ischemia are often elderly and frail, and early invasive open surgical procedures without adequate preoperative stabilization and preparation result in an unacceptably high risk of perioperative cardiopulmonary complications and death. Percutaneous methods designed to remove the intraluminal thrombus offer an alternative to immediate open surgical revascularization. These less invasive techniques constitute an option that is better tolerated in medically compromised patients. The causative lesion can be precisely identified and the patency of outflow vessels can be restored. The lesion can then be addressed on an elective basis in a well-prepared patient, using percutaneous or open surgical techniques to effect a durable long-term solution. The treatment options include primary surgical revascularization, thrombolytic therapy, percutaneous mechanical thrombectomy, or a combination of any of the three. Clinicians who themselves have the skills to perform a wide assortment of interventions ranging from percutaneous therapies through open surgical revascularization are best able to arrive at the most rational option for treating a specific clinical scenario. This article is directed at providing the practicing surgeon with a basic fund of knowledge on the diagnostic and therapeutic strategies useful in treating patients with peripheral arterial occlusion. Only in this manner can we expect to reduce the high rate of morbidity and mortality that remains associated with these events.
Collapse
Affiliation(s)
- Kenneth Ouriel
- Department of Vascular Surgery, The Cleveland Clinic Foundation, OH 44195, USA
| |
Collapse
|
17
|
Arko FR, Cipriano P, Lee E, Filis KA, Zarins CK, Fogarty TJ. Treatment of Axillosubclavian Vein Thrombosis:A Novel Technique for Rapid Removal of Clot Using Low-Dose Thrombolysis. J Endovasc Ther 2003. [DOI: 10.1583/1545-1550(2003)010<0733:toavta>2.0.co;2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
18
|
Wang M, Hays T, Balasa V, Bagatell R, Gruppo R, Grabowski EF, Valentino LA, Tsao-Wu G, Manco-Johnson MJ. Low-dose tissue plasminogen activator thrombolysis in children. J Pediatr Hematol Oncol 2003; 25:379-86. [PMID: 12759624 DOI: 10.1097/00043426-200305000-00006] [Citation(s) in RCA: 127] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE To compare results of low-dose tissue plasminogen activator (TPA) in children with arterial and venous thrombi relative to standard published dosing. METHODS Subjects consisted of all consecutive children with objectively confirmed thrombi for whom TPA thrombolysis was clinically ordered by the authors. Initial dosing used published standard dose (0.1-0.5 mg/kg per hour). With experience, a low-dose regimen (0.01-0.06 mg/kg per hour) was given in an attempt to derive a minimal effective dose. RESULTS Thirty-five children were treated with TPA. Either standard or low-dose infusions of TPA resulted in complete thrombolysis of 28 of 29 (97%) acute thrombi, while all 6 chronic thrombi had a partial response. In contrast to the recommended adult-derived dosages of 0.1 to 0.5 mg/kg per hour, the authors found that initial doses of less than 0.01 mg/kg per hour were effective in 12 of 17 patients with acute thrombosis. Neonates required 0.06 mg/kg per hour. Route of administration (local or systemic) did not affect efficacy. Major bleeding occurred in only one extremely preterm infant. Minor bleeding, primarily oozing at intravenous sites, occurred in 27% of children during TPA infusions. Prophylactic unfractionated or low-molecular-weight heparin was infused concomitant with TPA in 42% of the children and did not increase the risk of bleeding. CONCLUSIONS TPA in very low doses appears to be safe and effective for thrombolysis of acute thromboses in most children, given appropriate patient selection.
Collapse
Affiliation(s)
- Michael Wang
- Department of Pediatrics, Children's Hospital, University of Colorado Health Sciences Center, Denver, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Percutaneous mechanical thrombectomy is an established method in interventional radiology and refers to the removal of acute embolic or thrombotic occlusive material in arteries, veins, or vascular grafts using percutaneous transluminal methods. However, initial complete removal of occlusive material can be achieved only in a minority of patients. The amount of removed material varies with the age and composition of the occlusive material. To achieve sufficient revascularization, adjunctive use of a variety of percutaneous endovascular recanalization techniques is necessitated. Additional treatment with local intra-arterial fibrinolysis, balloon angioplasty, stent implantation, endoluminal atherectomy, and other measures results in primary technical success rates of 70% to 100% for revascularization of acutely occluded vessels. The above-mentioned different techniques should not be viewed as competitive treatment modalities, rather a synergistic approach should be offered. The aim of this report is to review different adjunctive techniques in percutaneous mechanical thrombectomy with emphasis on techniques, mechanisms of action, experimental and clinical results, potential complications, and their potential role in view of clinical pathways to treat acute limb ischemia.
Collapse
Affiliation(s)
- Marc Kalinowski
- Department of Diagnostic Radiology, University Hospital, Philipps University, Marburg, Germany
| | | |
Collapse
|
20
|
Semba CP, Weck S, Patapoff T. Alteplase: stability and bioactivity after dilution in normal saline solution. J Vasc Interv Radiol 2003; 14:99-102. [PMID: 12525593 DOI: 10.1097/01.rvi.0000052297.26939.05] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
PURPOSE To characterize the biochemical stability and bioactivity of reconstituted alteplase when diluted to a concentration of 0.01 mg/mL in normal saline solution and stored at ambient temperature for as long as 24 hours in commercial saline solution bags. MATERIALS AND METHODS Two commercially available formulations of lyophilized alteplase (2-mg and 50-mg vials, respectively) were reconstituted with sterile water to a final concentration of 1 mg/mL. For each vial configuration, 5 mg of alteplase (5 mL) was added to a commercial 500-mL bag of normal saline solution to achieve a 0.01-mg/mL targeted concentration. Solutions were assayed for optical clarity, pH, protein concentration, and in-vitro clot lysis activity. Assays of the solutions were performed at time points of 0 (control), 4, 8, and 24 hours at ambient room temperature and compared to controls. RESULTS On visual inspection, aliquots of the diluted protein solutions in clear glass vials remained clear/colorless after 24 hours. Bioactivity (clot lysis assay) over the course of 24 hours at ambient temperature remained essentially unchanged relative to control (2-mg vial: mean of 98.3%, range of 93.7%-103.3%; 50-mg vial: mean of 103.1%, range of 100.6%-108.3%). The mean protein recovery rates (relative to targeted concentration) over a 24-hour period were 43% (range, 39%-46%) and 42% (range, 40%-45%) for the 2-mg and 50-mg vial configurations, respectively. CONCLUSIONS Alteplase diluted in normal saline solution at a concentration of 0.01 mg/mL is biochemically stable and active at ambient temperature for as long as 24 hours as assessed by in vitro clot lysis assays. Alteplase appears to have a bimodal solubility profile in normal saline solution and further studies are required to determine the activity and solubility of alteplase concentrations lower than 0.01 mg/mL.
Collapse
Affiliation(s)
- Charles P Semba
- Department of Vascular Medicine, BioTherapeutic Unit , Genentech, South San Francisco, CA 94080-4990, USA.
| | | | | |
Collapse
|
21
|
Abstract
Acute peripheral arterial occlusion occurs as a result of thrombosis or embolism. A reduction in the prevalence of rheumatic heart disease accounts for a shift in the frequency of embolic to thrombotic occlusions. Also, a dramatic increase in the number of lower extremity arterial bypass graft procedures explains the predominance of graft occlusions in most recent series of patients with acute limb ischemia. While open surgical procedures remain the gold standard in the treatment of peripheral arterial occlusion, thrombolytic agents have been employed as an alternative to primary surgical revascularization in patients with acute limb ischemia. Systemic administration of thrombolytic agents, while effective for small coronary artery clots, fails to achieve dissolution of the large peripheral arterial thrombi. Catheter-directed administration of the agents directly into the occlusive thrombus is the only means of effecting early recanalization. Prior to 1999, urokinase was the sole agent used in North America for peripheral arterial indications, but the loss of the agent from the marketplace forced clinicians to turn to alternate agents, specifically alteplase and reteplase. Interest in the use of platelet glycoprotein inhibitors and mechanical thrombectomy devices also rose, coincident with the loss of urokinase from the marketplace. Most clinicians welcome the predicted return of urokinase to the marketplace. New investigative trials should be organized and executed to answer some of the remaining questions related to thrombolytic treatment of peripheral arterial disease. Foremost in this regard remains the question of which patients are best treated with percutaneous thrombolytic techniques and which are best treated with primary operative intervention. Ultimately, however, the thrombolytic agents are but one tool in the armamentarium of the vascular practitioner. This review is directed at providing the practicing clinician with the basic fund of knowledge necessary when determining the most appropriate intervention in a particular patient with peripheral arterial occlusion, be it thrombolytic therapy, percutaneous mechanical thrombectomy, primary surgical revascularization, or a combination of the three.
Collapse
Affiliation(s)
- Kenneth Ouriel
- Department of Vascular Surgery, Desk S40, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
| |
Collapse
|
22
|
Castañeda F, Swischuk JL, Li R, Young K, Smouse B, Brady T. Declining-dose study of reteplase treatment for lower extremity arterial occlusions. J Vasc Interv Radiol 2002; 13:1093-8. [PMID: 12427807 DOI: 10.1016/s1051-0443(07)61949-6] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
PURPOSE To prospectively determine the technical success and complication rates of three different reteplase dosing regimens during catheter-directed arterial thrombolysis. MATERIALS AND METHODS Prospective data were obtained from three groups of patients who underwent lower extremity arterial thrombolysis with three different regimens of reteplase: 0.5 U/h, 0.25 U/h, and 0.125 U/h. A total of 101 thrombosed lower extremity arterial occlusions in 87 patients were treated. A subtherapeutic intravenous heparin dose of 400-500 U/h was administered. All limbs were viable at presentation. Thrombolytic success was defined as 95% thrombolysis of the occluded artery or graft with restored distal antegrade flow. Thirty-day mortality and amputation rates were calculated. Bleeding complications and need for transfusions were recorded. Laboratory values recorded included fibrinogen level, platelet count, hematocrit level, hemoglobin level, and prothrombin time. RESULTS Thrombolytic success was achieved in 86.7% of patients in the 0.5-U/h dose group, 83.8% of patients in the 0.25-U/h dose group, and 85.3% of patients in the 0.125-U/h dose group. The major bleeding and transfusion rates were 13.3% in the 0.5-U/h dose group, 5.4% in the 0.25-U/h dose group, and 2.9% in the 0.125-U/h dose group. The 30-day amputation-free survival rates were 90% in the 0.5-U/h dose group, 97.3% in the 0.25-U/h dose group, and 94.1% in the 0.125-U/h dose group. Pre- and postprocedural fibrinogen levels and the fibrinogen nadir were not statistically different between the groups. No differences in total infusion times were found between the 0.5-U/h dose and 0.25-U/h dose groups. However, the infusion time in the 0.125-U/h dose group was significantly longer than in the other two groups (42 h vs 30 h; P <.05). CONCLUSION All dosing regimens were equally effective in the treatment of acute lower extremity occlusions. The infusion times were longer with the 0.125-U/h dose. Significantly fewer major bleeding complications were encountered with the 0.25-U/h and 0.125-U/h dose regimens than with the 0.5-U/h dose regimen.
Collapse
Affiliation(s)
- Flavio Castañeda
- Department of Radiology, University of Illinois College of Medicine at Peoria, 1 Illini Drive, Box 1649, Peoria, Illinois 61656, USA.
| | | | | | | | | | | |
Collapse
|
23
|
Sharafuddin MJ, Sun S, Hoballah JJ. Endovascular management of venous thrombotic diseases of the upper torso and extremities. J Vasc Interv Radiol 2002; 13:975-90. [PMID: 12397118 DOI: 10.1016/s1051-0443(07)61861-2] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Central venous thrombosis in the upper torso can be either primary, occurring as a result of longstanding extrinsic compression, or secondary, resulting from an acquired intrinsic occlusive disease or foreign body. As in lower extremity deep vein thrombosis (DVT), anticoagulation therapy is the mainstay of therapy in upper torso and upper extremity DVT. However, in the presence of severely symptomatic acute thrombosis, pharmacologic and/or mechanical thrombolytic therapy represent the main invasive form of therapy for these conditions. After clearance of the acute thrombotic component, definitive management in patients with underlying anatomic abnormalities can be undertaken. Primary subclavian axillary vein thrombosis caused by extrinsic obstruction at the thoracic outlet is treated with thrombolytic therapy and anticoagulation followed by surgical decompression, whereas secondary causes of central venous obstruction and thrombosis are usually amenable to endovascular treatment with balloon angioplasty and stent placement. Postoperative interval anticoagulation is usually recommended. In addition to clinical follow-up, imaging follow-up with duplex sonography or conventional venography is usually recommended to assess the presence of restenosis and/or residual compression.
Collapse
Affiliation(s)
- Melhem J Sharafuddin
- Department of Radiology, University of Iowa College of Medicine, 3889 JPP, 200 Hawkins Drive, Iowa City, Iowa 52242-1077, USA.
| | | | | |
Collapse
|
24
|
Castaneda F, Li R, Young K, Swischuk JL, Smouse B, Brady T. Catheter-directed thrombolysis in deep venous thrombosis with use of reteplase: immediate results and complications from a pilot study. J Vasc Interv Radiol 2002; 13:577-80. [PMID: 12050297 DOI: 10.1016/s1051-0443(07)61650-9] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
PURPOSE To prospectively determine the thrombolytic success and complication rates of catheter-directed thrombolytic infusions in deep vein thrombosis (DVT) with use of reteplase. MATERIALS AND METHODS After approval by the institutional review board, prospective, detailed data were obtained for 25 consecutive patients with acute and chronic DVT of the upper or lower extremity (seven upper extremity; 14 lower extremity; four vena cava). Infusion rates were 1.0 U/h in five patients and 0.5 U/h in the remaining 20. Subtherapeutic heparin doses of 300-400 U/h were administered. Thrombolytic success was defined as 95% thrombolysis with return of antegrade flow. Data, including complications such as bleeding, need for transfusions, and laboratory values (fibrinogen, platelets, hematocrit, hemoglobin, and prothrombin time) were obtained throughout the infusions. RESULTS The total dose of reteplase administered ranged from 2.5 to 42 U (median, 16.5 U). The total infusion time ranged from 0.3 to 84 hours (median, 29 h). Thrombolytic success was achieved in 92% of patients. Endovascular stent placement and/or percutaneous transluminal angioplasty were required in 52% of patients to ensure maintenance of patency. Pre- and postprocedural average fibrinogen levels were 340 mg/dL and 315.3 mg/dL, respectively. The lowest mean fibrinogen levels for the two dose groups were 265.86 mg/dL for the 0.5 U/h group and 314.18 mg/dL for the 1.0 U/h group. The lowest fibrinogen level during the procedure was 252.3 mg/dL (range, 35 to >700). There were only two instances of fibrinogen levels that decreased to below 90 mg/dL: 35 mg/dL and 43 mg/dL. Thrombolytic failures occurred in two patients: one with acquired immune deficiency syndrome in a hypercoagulable state and one with a major bleeding complication. This was the only patient with a bleeding complication (4%). Hemorrhage occurred from the site of a previous mediastinal biopsy-which should have rendered her ineligible for the study-performed 18 hours before the thrombolysis. If thrombolysis had not been attempted in this patient, the complication rate would have been 0%. CONCLUSION Although there are reports of thrombolytic therapy in peripheral vascular occlusive disease, this study is one of the first to evaluate thrombolytic drugs in the deep venous system exclusively. Reteplase was found to be effective in the thrombolytic treatment of acute and chronic DVT.
Collapse
Affiliation(s)
- Flavio Castaneda
- Department of Radiology, University of Illinois College of Medicine at Peoria, 1 Illini Drive, Box 1649, Peoria, Illinois 61656, USA.
| | | | | | | | | | | |
Collapse
|
25
|
Bussard ME. Reteplase: Nursing Implications for Catheter-Directed Thrombolytic Therapy for Peripheral Vascular Occlusions. Crit Care Nurse 2002. [DOI: 10.4037/ccn2002.22.3.57] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Affiliation(s)
- Michelle E. Bussard
- Michelle E. Bussard is an adult clinical nurse specialist. She currently works in a medical-surgical intensive care unit at St. John West Shore Hospital in Westlake, Ohio. She has been a registered nurse for 6 years
| |
Collapse
|
26
|
Yoon HC, Miller FJ. Using a peptide inhibitor of the glycoprotein IIb/IIIa platelet receptor: initial experience in patients with acute peripheral arterial occlusions. AJR Am J Roentgenol 2002; 178:617-22. [PMID: 11856686 DOI: 10.2214/ajr.178.3.1780617] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVE The purpose of this study was to evaluate the efficacy of eptifibatide, an inhibitor of the glycoprotein (GP) IIb/IIIa platelet receptor, in the thrombolytic treatment of patients with acute peripheral arterial occlusive disease. MATERIALS AND METHODS We retrospectively reviewed our experience with the use of a GP IIb/IIIa receptor inhibitor, eptifibatide, during thrombolysis in 17 patients with acute lower extremity arterial occlusions who also received intraarterial recombinant tissue plasminogen activator (rt-PA) and heparin. Four of the 17 patients received their loading dose of eptifibatide by direct intraarterial injection, whereas the remaining 13 received an IV loading dose. We compared their results with those of 11 other patients who received only rt-PA and heparin with respect to success and complication rates, duration of thrombolytic therapy, and total rt-PA dose. RESULTS We found no significant difference in successful outcome (p = 1.00), major complications (p = 1.00), duration of therapy (p = 0.21), or total rt-PA dose (p = 0.67) between those who received eptifibatide and those who did not during thrombolytic therapy. However, those patients who received an intraarterial loading dose of eptifibatide required substantially less rt-PA (9.0 +/- 4.4 mg vs 38.9 +/- 30.7 mg) to achieve successful thrombolysis. CONCLUSION The adjunctive use of a GP IIb/IIIa platelet receptor inhibitor during thrombolysis for arterial occlusions may decrease the total dose of rt-PA required for thrombolysis without compromising success or complication rates. A prospective randomized study is needed to confirm that inhibitors of the GP IIb/IIIa platelet receptor can facilitate thrombolytic therapy in patients with acute lower extremity arterial occlusions.
Collapse
Affiliation(s)
- Hyo-Chun Yoon
- Department of Radiology, University of Utah School of Medicine, 1A-71 SOM, 50 N. Medical Dr., Salt Lake City, UT 84132, USA
| | | |
Collapse
|
27
|
Arepally A, Hofmann LV, Kim HS, Geschwind JF, Kirkwood S, Oechsle D, Perler B. Weight-based rt-PA thrombolysis protocol for acute native arterial and bypass graft occlusions. J Vasc Interv Radiol 2002; 13:45-50. [PMID: 11788694 DOI: 10.1016/s1051-0443(07)60008-6] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
PURPOSE To determine technical success and complications with weight-adjusted dosing of recombinant tissue plasminogen activator (rt-PA) for arterial and bypass graft occlusions. MATERIALS AND METHODS During an 8-month period, prospective data were collected on patients undergoing catheter-directed thrombolysis. Retrospective review of all medical charts and blood bank data were performed for confirmation. All patients underwent a standard weight-adjusted protocol for catheter-directed thrombolysis. Thrombolytic therapy with rt-PA (0.2 mg/mL) was defined as low-dose when 0.02 mg/kg/h rt-PA was used and high-dose when 0.04 mg/kg/h of rt-PA was used. Low-dose heparin therapy was used. Total infusion time, total dose, and hourly rate of dose were calculated. Technical success, defined as complete removal of all clot without surgical intervention, complications, and frequency of transfusions were tabulated. RESULTS A total of 35 patients underwent catheter-directed thrombolysis with rt-PA, including a total of 21 bypass grafts (60%) and 14 native arteries (40%). Mean age was 57 years (+/- 22.5; range, 3 mo to 83 y). Average rate of heparin infusion was 472.8 U/h (+/- 227). Success rates for graft thrombolysis were 90% (18 of 21). Success rates for native vessels were 79% (11 of 14). In patients who underwent only a low-dose protocol, the transfusion rate was 15% and major complications were 10%. In patients with a combined low-dose/high-dose administration, the transfusion rate was 46% and major complications were 13%. Overall success rate and major complication rates were 86% (30 of 35) and 11% (four of 35), respectively. Frequency of transfusions was 37% (13 of 35; mean, 2.8 U). CONCLUSION Although weight-adjusted dosing for rt-PA provides a high efficacy of relieving ischemia, the rate of complications, especially bleeding, seems excessive in comparison to historical experience with urokinase. Administration of short-term high doses of rt-PA did not appear to have any beneficial effect. Further investigation with lower dosing and concentration should be considered.
Collapse
Affiliation(s)
- Aravind Arepally
- Russell H. Morgan Department of Radiology and Radiological Science, Division of Cardiovascular and Interventional Radiology, Johns Hopkins Medical Institutes, Baltimore, Maryland, USA.
| | | | | | | | | | | | | |
Collapse
|
28
|
Bookstein JJ, Bookstein FL. Pulse-spray thrombolysis with reteplase: optimization and comparison with tPA in a rabbit model. J Vasc Interv Radiol 2001; 12:1319-24. [PMID: 11698632 DOI: 10.1016/s1051-0443(07)61558-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
PURPOSE To critically evaluate and optimize methodology for pulse-spray thrombolysis with reteplase in a rabbit inferior vena cava (IVC) thrombosis model and to compare results with optimized parameters for the use of tissue plasminogen activator (tPA). MATERIALS AND METHODS Occlusive IVC thrombus was produced in 102 rabbits and treated 2 days later for 1 hour with pulse-spray thrombolysis using reteplase. Methodologic variables included pulse frequency, concentration and amount of reteplase, infusion versus pulse therapy, and admixture of heparin. After the rabbits were killed, residual thrombus was weighed and percent lysis was estimated on the basis of previous control values. Results were compared with those achieved with tPA in 18 additional rabbits and also with previous tPA results. RESULTS As in earlier tPA studies, pulse-spray methods were far more effective than constant infusion. Pulses at 30-second intervals produced better results than pulses at 2-minute intervals. At the optimal concentration of 0.02 U/mL (molarity 90 x 10(-8) ), reteplase produced 79% lysis. At two-fold higher or lower concentrations, lysis was reduced by approximately 25%, and at eight-fold higher or six-fold lower concentrations, lysis was reduced by approximately 50%. Optimal concentration of tPA was 0.02 mg/mL, yielding 78% lysis. Admixture of reteplase with heparin suggested improvement, but differences were statistically insignificant. CONCLUSION When used with pulse-spray methodology, reteplase demonstrated a steep bell-shaped response-concentration curve similar in pitch and amplitude to that of tPA. The optimal molar concentration of reteplase was approximately three times that of tPA. However, at their respective optimal concentrations, reteplase and tPA were equally effective.
Collapse
Affiliation(s)
- J J Bookstein
- Division of Research, VA Hospital, La Jolla, and the Hospital of the University of California San Diego, San Diego, California, USA.
| | | |
Collapse
|
29
|
Falk A, Guller J, Nowakowski FS, Mitty H, Teodorescu V, Uribarri J, Vassalotti J. Reteplase in the treatment of thrombosed hemodialysis grafts. J Vasc Interv Radiol 2001; 12:1257-62. [PMID: 11698623 DOI: 10.1016/s1051-0443(07)61548-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
PURPOSE To prospectively evaluate the efficacy and safety of reteplase with percutaneous transluminal angioplasty (PTA) in the treatment of thrombosed polytetrafluoroethylene hemodialysis arteriovenous grafts (AVGs). MATERIALS AND METHODS Forty-two patients were entered into the study. Sixty-two procedures in 43 grafts were performed. One unit of reteplase and 4,000 units of heparin were administered into the AVGs. Routine venography and percutaneous transluminal angioplasty (PTA) was then performed. Patients were transferred for hemodialysis immediately after the procedure. RESULTS Technical success was achieved in 92% of the cases. Four cases involved intentional repeat thrombosis because of poor outflow and/or need for a new graft site. Minor complications occurred in 6.5% of the cases. No major complications occurred. The mean procedure time for experienced versus less-experienced interventionalists was significantly shorter (P <.001). Primary patency rates were 50%, 34%, and 34% at 30, 90, and 180 days, respectively. CONCLUSION Reteplase in conjunction with heparin and PTA is a safe and effective means of thrombolysis of AVGs. Its efficacy is comparable to that of other available thrombolytic drugs.
Collapse
Affiliation(s)
- A Falk
- Department of Radiology, Mount Sinai-NYU Medical Center, One Gustave L. Levy Place, New York, New York 10029-6574, USA.
| | | | | | | | | | | | | |
Collapse
|
30
|
Benenati J, Shlansky-Goldberg R, Meglin A, Seidl E. Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Society for Cardiovascular and Interventional Radiology. J Vasc Interv Radiol 2001; 12:795-805. [PMID: 11435535 DOI: 10.1016/s1051-0443(07)61503-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023] Open
Affiliation(s)
- J Benenati
- Peripheral Vascular Laboratory, Miami Cardiac and Vascular Institute, Miami, Florida 33176, USA.
| | | | | | | |
Collapse
|
31
|
Swischuk JL, Fox PF, Young K, Hussain S, Smouse B, Castañeda F, Brady TM. Transcatheter intraarterial infusion of rt-PA for acute lower limb ischemia: results and complications. J Vasc Interv Radiol 2001; 12:423-30. [PMID: 11287527 DOI: 10.1016/s1051-0443(07)61879-x] [Citation(s) in RCA: 62] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
PURPOSE To determine the success and complication rates of intraarterial recombinant tissue-type plasminogen activator (rt-PA) infusion for the treatment of acute lower extremity artery and bypass graft occlusions. MATERIALS AND METHODS The results of 74 limbs in 70 patients (mean age, 66 y) treated with catheter-directed rt-PA infusion for the treatment of acute lower extremity ischemia were retrospectively evaluated. The group included 42 bypass grafts and 32 native arteries. All limbs were viable at presentation. The mean duration of symptoms was 11.9 days. rt-PA was infused for a mean of 27.9 hours for a mean total dose of 38.7 mg. Initial infusion rates of 3-6 mg/h were lowered to a preferred rate of 1.5 mg/h. Thrombolytic success was defined as 95% thrombolysis of an occluded segment with return of antegrade flow. Major bleeding complications were defined as any hemorrhagic event leading to surgery, extended or unexpected hospitalization, transfusion, death, intracranial hemorrhage, or a decrease in hemoglobin of 5 g/dL or in hematocrit of 15%. Thirty-day mortality and amputation rates were calculated. Patient characteristics and infusion parameters were evaluated as to whether they contributed to thrombolytic success or major bleeding events. RESULTS Thrombolytic success was achieved in 64 limbs (86%). Major bleeding complications occurred in 33 (47%) patients. In 22 of these patients, bleeding occurred at a vascular puncture site, whereas remote bleeding occurred in seven patients. Remote bleeding complications included two retroperitoneal hematomas, two rectus sheath hematomas, one lower gastrointestinal hemorrhage, one episode of hemoptysis, and one dehiscence of a femoral-popliteal bypass graft revision. No parameters were found to be predictive of thrombolytic success, whereas a negative history of smoking, increasing duration of infusion, and a low preprocedural ankle-brachial index (ABI) were found to be associated with major hemorrhagic events. Four patients (6%) underwent amputation and one patient (1%) died, resulting in a 30-day amputation-free survival rate of 93%. CONCLUSION Catheter-directed rt-PA infusion is effective in achieving thrombolysis. Despite a significant number of bleeding complications, 30-day mortality and amputation rates were favorable. Nonetheless, complication rates related to bleeding were not trivial and further evaluation with use of variable dosing regimens is indicated.
Collapse
Affiliation(s)
- J L Swischuk
- Department of Radiology, University of Illinois College of Medicine at Peoria, 1 Illini Dr., Peoria, IL 61605, USA.
| | | | | | | | | | | | | |
Collapse
|
32
|
Timms ID. Low-Molecular-Weight Heparins: Overview and Potential Uses in Interventional Radiology. J Vasc Interv Radiol 2001. [DOI: 10.1016/s1051-0443(01)70027-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|